Breast Cancer
Conditions
Keywords
recurrent breast cancer, stage IV breast cancer
Brief summary
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using exemestane may fight breast cancer by lowering the amount of estrogen the body makes. PURPOSE: This phase II trial is studying how well exemestane works in treating postmenopausal women with stage IV breast cancer.
Detailed description
PRIMARY OBJECTIVES: I. Progression-free survival at 4 months, as measured by Response Evaluation Criteria in Solid Tumors (RECIST). SECONDARY OBJECTIVES: I. Objective response rate (complete response \[CR\] and partial response \[PR\]). II. Clinical benefit (CR, PR, and stable disease \>= 6 months). III. Assessment of toxicity. IV. Assessment of compliance with medication adherence. V. Assessment of quality of life. VI. Assessment of bone health. TERTIARY OBJECTIVES: I. Serial measurements of serum estradiol, estrone, and estrone sulfate. II. To investigate treatment resistance (e.g., expression of amphiregulin, epidermal growth factor receptor \[EGFR\]), using molecular and immunohistochemical analyses of blood and tumor samples of pre- and post- (when available) treatment tissues. Microarray analyses to quantitate the expression of specific estrogen-responsive genes (e.g. thyroid transcription factor 1 \[TTF1\] and PDZK1) will also be performed. OUTLINE: Patients receive exemestane orally (PO) once daily (QD) on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study therapy, patients are followed periodically for 1 year.
Interventions
DRUGexemestane
Given orally
OTHERlaboratory biomarker analysis
One year after completion of study treatment
PROCEDUREquality-of-life assessment
One year after completion of study treatment
OTHERimmunohistochemistry staining method
Correlative studies
Sponsors
National Cancer Institute (NCI)
City of Hope Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically confirmed metastatic carcinoma of the breast * Hormone receptor (estrogen receptor \[ER\] and/or progesterone receptor \[PR\]) positive disease (defined as: ER and/or PR positivity as \>= 5% staining), as confirmed by immunohistochemistry (IHC) based on primary breast tissue or metastatic tissue * Postmenopausal, as defined by any of the following: * Natural menopause, with at least 1 year since last menses * Chemotherapy-induced menopause with at least 1 year from last menses and serum luteinizing hormone (LH)/follicle-stimulating hormone (FSH) and estradiol levels within the postmenopausal range * History of surgical or radiation-induced ovarian ablation * For women =\< 56 years old and with a history of hysterectomy but at least one ovary intact, serum LH/FSH and estradiol levels must be within the postmenopausal range * Postmenopausal women with disease recurrence while receiving either tamoxifen or a non-steroidal aromatase inhibitor (AI) as adjuvant therapy (as long as adjuvant hormonal therapy was taken for 6 months before disease progression) or with disease recurrence following the discontinuation/completion of adjuvant hormonal therapy * Postmenopausal women with disease progression following either 0, 1 or 2 prior hormonal therapies for metastatic breast cancer, as long as the subject has had no prior exposure to exemestane (EXE) * Measurable or non-measurable (but evaluable) disease, as defined by RECIST criteria * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Neutrophil count \>= 1.5 X 10\^9 cells/L * Platelet count \>= 100 X 10\^9 cells/L * Serum creatinine =\< 1.5 times upper limit of normal (ULN) * Total serum bilirubin =\< 1.5 times ULN * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) levels =\< 2.5 x ULN in patients without liver metastases or =\< 5 times ULN in patients with liver metastases * Alkaline phosphatase =\< 2.5 times the ULN for patients without bone or liver metastases * Subjects must have an estimated life expectancy of greater than 6 months
Exclusion criteria
* Prior exposure to EXE, whether in the adjuvant or metastatic setting * Prior history of any other cancer with the exception of non-melanoma skin cancer and treated in situ carcinoma of the cervix * Active or symptomatic central nervous system (CNS) metastasis (stable or treated brain metastasis allowed but patients must be off decadron, if given for CNS disease) * Hormone-receptor negative or unknown breast cancer * More than two prior chemotherapy regimen for treatment of metastatic disease (any prior chemotherapy given in the adjuvant setting is permitted) * Administration of any other anti-cancer therapy within 2 weeks of initiating study treatment; use of bisphosphonates, however, are permitted for patients with known bone metastases * Treatment with any other concurrent investigational agent or anti-tumor drug (chemotherapy, antibody therapy or other biologic agents), will not be permitted * Subjects who have had no prior exposure to endocrine therapy * Any uncontrolled medical co-morbidity or psychiatric disorder which interferes with the ability to provide informed consent or comply with study procedures
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival | Until disease progression of death from any cause, up to 3 years | Estimated using the product-limit method of Kaplan and Meier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate | Until disease progression or off treatment, assessed up to 1 year | Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Treatment (Exemestane) Patients receive 25mg oral exemestane once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
exemestane: Given orally
laboratory biomarker analysis: One year after completion of study treatment
quality-of-life assessment: One year after completion of study treatment
immunohistochemistry staining method: Correlative studies | 36 |
| Total | 36 |
Baseline characteristics
| Characteristic | Treatment (Exemestane) |
|---|---|
| Age, Continuous | 60 years |
| Race/Ethnicity, Customized African American | 1 Participants |
| Race/Ethnicity, Customized Asian | 4 Participants |
| Race/Ethnicity, Customized Caucasian | 13 Participants |
| Race/Ethnicity, Customized Hispanic | 15 Participants |
| Race/Ethnicity, Customized Other | 3 Participants |
| Region of Enrollment United States | 36 participants |
| Sex: Female, Male Female | 36 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 30 / 36 |
| other Total, other adverse events | 35 / 36 |
| serious Total, serious adverse events | 4 / 36 |
Outcome results
Primary
Progression-free Survival
Estimated using the product-limit method of Kaplan and Meier. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: Until disease progression of death from any cause, up to 3 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Exemestane) | Progression-free Survival | 4.3 months |
Secondary
Overall Response Rate
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
Time frame: Until disease progression or off treatment, assessed up to 1 year
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Exemestane) | Overall Response Rate | 8.3 percentage of participants |